---
title: "Oramed Pharmaceuticals COO & Cbo Sold Shares Worth Over $611K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291590990.md"
description: "Oramed Pharmaceuticals COO & CBO Hexter Joshua sold 137,000 shares worth $611,431 on July 1, 2026, under a Rule 10b5-1 plan. The weighted average sale price was $4.463 per share. Following the transaction, Joshua retains direct ownership of 1,023,384 common shares."
datetime: "2026-07-02T21:10:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291590990.md)
  - [en](https://longbridge.com/en/news/291590990.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291590990.md)
---

# Oramed Pharmaceuticals COO & Cbo Sold Shares Worth Over $611K

Hexter Joshua, an officer serving as COO & CBO, reported the sale under a Rule 10b5-1 plan adopted March 30, 2026. The shares were sold at a weighted average price of $4.463 per share, with individual sale prices ranging from $4.255 to $4.7652. The total sale amount reported was $611,431 for 137,000 shares sold on July 1, 2026. After the transaction, Hexter Joshua directly owned 1,023,384 shares of common stock.

Reporter Name

Hexter Joshua

Relationship

COO & CBO

Type

Sell

Amount

$611,431

SEC Filing

Form 4

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ORMP.US](https://longbridge.com/en/quote/ORMP.US.md)

## Related News & Research

- [Oramed CFO Avraham Gabay sells 73,360 shares for $330,646.76](https://longbridge.com/en/news/291589297.md)
- [Oramed amends bylaws to streamline written-consent record date, delivery rules](https://longbridge.com/en/news/291329634.md)
- [Israel "Izzy" Englander increased his position in this pharma stock by 780%. Does he know something Wall Street doesn't?](https://longbridge.com/en/news/293842675.md)
- [AstraZeneca CFO says AI is not expected to lead to job cuts](https://longbridge.com/en/news/293905971.md)
- [CMRE: Q2 2026 delivered strong earnings, robust liquidity, and major fleet financing amid a tight charter market](https://longbridge.com/en/news/293930043.md)